Rifapentine(CAS: 61379-65-5)

Rifapentine (CAS: 61379-65-5) is subject to various regulatory guidelines including GHS classification, REACH regulations, and FDA/EPA requirements. It is classified as a pharmaceutical substance and must comply with strict safety and quality standards. Specific regulations include documentation of safety data sheets (SDS), adherence to Good Manufacturing Practices (GMP), and adherence to transportation and storage guidelines to ensure safety and efficacy.

In synthesis, Rifapentine (CAS: 61379-65-5) can be synthesized using analogs such as rifaprost and rifapentine derivatives. Common alternative reagents include halides, sulfonates, and carboxylates. For safer and more efficient synthesis, isomers like rifapentine-A and rifapentine-B can also be used as alternatives.

The market for Rifapentine (CAS: 61379-65-5) is growing due to its effectiveness in treating tuberculosis and other bacterial infections. Research trends focus on optimizing its delivery systems, such as lipid formulations and inhalation therapies. Recent studies are also exploring its use in combination with other drugs to improve treatment outcomes and reduce resistance. Market demand is robust, with a growing emphasis on personalized and targeted therapies.

Waste containing Rifapentine (CAS: 61379-65-5) should be collected in designated, leak-proof containers and stored in a secure, well-ventilated area. Proper incineration or professional waste disposal is recommended, adhering to local environmental regulations. Precautions include wearing appropriate protective gear and ensuring proper ventilation to prevent inhalation or skin contact. Environmental protection measures include monitoring for any potential contamination and following best practices for waste management to minimize ecological impact.